Clinical Trial Update: Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating Zevalin for non-Hodgkin lymphoma has been terminated; the update discusses safety and efficacy outcomes from the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Biogen | Conditions: Non-Hodgkin's Lymphoma | Phase 3 | Status: TERMINATED